- Home
- SNTI vs IHD Comparison
SNTI vs IHD Comparison
Compare SNTI & IHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- IHD
- Stock Information
- Founded
- SNTI 2016
- IHD 2011
- Country
- SNTI United States
- IHD United States
- Employees
- SNTI N/A
- IHD N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- IHD Investment Managers
- Sector
- SNTI Health Care
- IHD Finance
- Exchange
- SNTI Nasdaq
- IHD Nasdaq
- Market Cap
- SNTI 85.3M
- IHD 89.3M
- IPO Year
- SNTI N/A
- IHD N/A
- Fundamental
- Price
- SNTI $3.10
- IHD $5.46
- Analyst Decision
- SNTI Strong Buy
- IHD
- Analyst Count
- SNTI 1
- IHD 0
- Target Price
- SNTI $12.00
- IHD N/A
- AVG Volume (30 Days)
- SNTI 225.5K
- IHD 27.7K
- Earning Date
- SNTI 05-06-2025
- IHD 01-01-0001
- Dividend Yield
- SNTI N/A
- IHD 10.32%
- EPS Growth
- SNTI N/A
- IHD N/A
- EPS
- SNTI N/A
- IHD N/A
- Revenue
- SNTI N/A
- IHD N/A
- Revenue This Year
- SNTI N/A
- IHD N/A
- Revenue Next Year
- SNTI N/A
- IHD N/A
- P/E Ratio
- SNTI N/A
- IHD N/A
- Revenue Growth
- SNTI N/A
- IHD N/A
- 52 Week Low
- SNTI $1.52
- IHD $4.49
- 52 Week High
- SNTI $16.94
- IHD $5.47
- Technical
- Relative Strength Index (RSI)
- SNTI 41.06
- IHD 67.14
- Support Level
- SNTI $3.10
- IHD $5.13
- Resistance Level
- SNTI $3.61
- IHD $5.33
- Average True Range (ATR)
- SNTI 0.40
- IHD 0.08
- MACD
- SNTI -0.07
- IHD 0.04
- Stochastic Oscillator
- SNTI 9.50
- IHD 100.00
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About IHD Voya Emerging Markets High Income Dividend Equity Fund
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.